Conventional tumor models with immunodeficient animals only monitor the effect of a drug on the tumor itself. The approval in 2011 of the first immune-checkpoint inhibitor (Nobel Prize Winner in 2018) has validated the immuno-oncology therapeutic approach against many forms of cancer.
TransCure bioServices has developed one of the most predictive preclinical immuno-oncology mouse models. Engraftment of tumor cells lines (CDX) or patient-derived xenografts (PDX) in our CD34+ humanized mouse models fully recapitulate the cancer disease.
Thanks to our strong expertise in CD34+ humanized mouse models, TransCure BioServices can provide custom study designs in order to: analyze PK/PD response of your drug candidates, assess the therapeutic efficacies, and/or decipher their mechanisms of action.
Make sure to check out our complimentary webinar “How Humanized Mouse Models Enforce Preclinical Studies in Immuno-Oncology“, a 2 minute introduction is provided here.
Preclinical IO study
We have a list of fully characterized tumor cell lines and can provide access to their tumor micro-environment (TME) infiltration data, so you can choose the best tumor model for your specific needs.
Drug testing in our humanized mouse models will allow you test mechanisms of actions such as: Immune-checkpoint inhibitors (ICP), ADCC, Phagocytosis, T-cell engagers, NK-bispecifics, cytokines, cell therapies, and CAR-based therapies.
Immune-checkpoint inhibitor and T cells exhaustion
CAR-T cells and hu-mouse models
Other mouse models are also available:
- Engraftment of PDX in CD34+ humanized mice
- Engraftment PDX/CDX in immunodeficient mice
- Syngeneic mouse models
- Human PBMC engrafted mouse models